Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Rivus Pharmaceuticals logo — Developing new oral medicines to advance cardiometabolic hea...

Rivus Pharmaceuticals

Developing new oral medicines to advance cardiometabolic health

Founded 2019 United States Charlottesville, United States 29 employees Series B Total: $167.00M Biotechnology, Health Care +1

General Information

Company Name Rivus Pharmaceuticals
Founded Year 2019
Location United States Charlottesville, United States
Employees 29
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Rivus Pharmaceuticals. To contact Rivus Pharmaceuticals, visit rivuspharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Rivus Pharmaceuticals

Rivus Pharmaceuticals, Inc., founded in 2019, is dedicated to transforming the treatment of cardio-metabolic disease with its innovative approach. The company focuses on advancing a new class of oral, once daily, small molecule therapeutics known as Controlled Metabolic Accelerators (CMAs). These CMAs are designed to improve cellular metabolism and treat the underlying cause of prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), and cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF). In their most recent funding round, Rivus Pharmaceuticals secured a noteworthy $132.00M Series B investment on 22 September 2022. The investment was backed by prominent firms such as Longitude Capital, RA Capital Management, BB Biotech Ventures, RxCapital, Medicxi, and Bain Capital Life Sciences. For more information about Rivus Pharmaceuticals, please visit their website at https://www.rivuspharma.com/. The company operates primarily in the Biotechnology, Health Care, and Pharmaceutical industries.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $132.00M 6
Longitude Capital RA Capital Management BB Biotech Ventures
Longitude Capital, RA Capital Management +4
22 Sep 2022
Series A $35.00M 3
Longitude Capital RxCapital
Longitude Capital, RxCapital +1
20 Jul 2021

FAQ About Rivus Pharmaceuticals

Developing new oral medicines to advance cardiometabolic health
Rivus Pharmaceuticals was founded in 2019.
Rivus Pharmaceuticals is headquartered in Charlottesville, United States.
Rivus Pharmaceuticals operates in Biotechnology, Health Care and Pharmaceutical.
Rivus Pharmaceuticals has approximately 29 employees.
Rivus Pharmaceuticals has completed 2 funding rounds, raising a total of $167.00M. The latest funding stage is Series B.

We're actively collecting intelligence on Rivus Pharmaceuticals.

Source: BounceWatch company record for Rivus Pharmaceuticals, https://bouncewatch.com/company/rivus-pharmaceuticals, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes